Legal Representation
Attorney
Stephen P. McNamara
USPTO Deadlines
Next Deadline
322 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2020-06-16)
Due Date
June 16, 2026
Grace Period Ends
December 16, 2026
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
22 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jun 16, 2025 | REM1 | E | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | Loading... |
| Jun 16, 2020 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Mar 31, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Mar 31, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Mar 11, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Feb 27, 2020 | FIXD | O | ELECTRONIC RECORD REVIEW COMPLETE | Loading... |
| Feb 7, 2020 | ERRR | O | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | Loading... |
| Jan 31, 2020 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jan 31, 2020 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Jan 31, 2020 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jan 31, 2020 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jan 31, 2020 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Jan 9, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jan 8, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jan 8, 2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jul 10, 2019 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jul 10, 2019 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jul 10, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jul 9, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| May 15, 2019 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| May 14, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Apr 30, 2019 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations and substances for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; pharmaceutical preparations, namely, a drug delivery system comprising pharmaceutical compositions for subcutaneous or intraarticular administration for the continuous release of therapeutic agents for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; veterinary preparations and substances for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; veterinary preparations, namely, a drug delivery system comprising compositions that facilitate continuous release delivery of a wide variety of therapeutic subcutaneous or intraarticular veterinary agents; pharmaceutical compositions for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceutical and veterinary pharmaceutical preparations; Drug delivery agents in the form of compounds that facilitate controlled release delivery of subcutaneous or intraarticular active ingredients for a wide variety of pharmaceuticals and veterinary pharmaceutical preparations; Drug delivery agents in the form of drug delivery compounds that facilitate sustained or extended release of the active ingredients for a wide variety of pharmaceuticals and veterinary pharmaceutical preparations; Drug delivery agents in the form of compounds that facilitate delivery of injectable pharmaceutical and veterinary pharmaceutical preparations; sustained or extended release drug delivery agents being compounds used to facilitate delivery of drugs, sold as an integral component of pharmaceutical and veterinary pharmaceutical preparations for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; chemical preparations for medical or pharmaceutical use for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; Carriers and mediums being drug delivery agents comprised of compounds for facilitating the delivery of pharmaceutical and veterinary pharmaceutical preparations for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; pharmaceutical and veterinary pharmaceutical preparations and substances for subcutaneous delivery for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders
Additional Information
Design Mark
The mark consists of the word "MedinCell" in black letters with a blue design consisting of two horizontally oriented conjoined semi-circles located above the word "Cell" with a single vertically oriented semi-circle conjoined to the right of the two horizontally oriented conjoined semi-circles.
Color Claim
The color(s) black and blue is/are claimed as a feature of the mark.
Classification
International Classes
005